A detailed history of Bank Of Nova Scotia transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bank Of Nova Scotia holds 4,877 shares of NBIX stock, worth $612,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,877
Previous 14,760 66.96%
Holding current value
$612,112
Previous $2.03 Million 72.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $1.13 Million - $1.51 Million
-9,883 Reduced 66.96%
4,877 $561,000
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $983,282 - $1.08 Million
7,514 Added 103.7%
14,760 $2.03 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $126,488 - $139,427
-970 Reduced 11.81%
7,246 $999,000
Q4 2023

Feb 12, 2024

BUY
$106.07 - $132.76 $189,334 - $236,976
1,785 Added 27.76%
8,216 $1.08 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $224,237 - $279,283
-2,385 Reduced 27.05%
6,431 $723,000
Q2 2023

Aug 03, 2023

SELL
$89.53 - $104.87 $10.6 Million - $12.5 Million
-118,734 Reduced 93.09%
8,816 $831,000
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $1.2 Million - $1.57 Million
-12,768 Reduced 9.1%
127,550 $12.9 Million
Q4 2022

Feb 09, 2023

SELL
$106.72 - $127.06 $12.3 Million - $14.6 Million
-114,985 Reduced 45.04%
140,318 $16.8 Million
Q3 2022

Nov 10, 2022

BUY
$92.03 - $107.81 $22.4 Million - $26.3 Million
243,505 Added 2063.95%
255,303 $27.1 Million
Q2 2022

Aug 08, 2022

BUY
$75.79 - $100.07 $894,170 - $1.18 Million
11,798 New
11,798 $1.15 Million
Q2 2022

Aug 05, 2022

SELL
$75.79 - $100.07 $931,080 - $1.23 Million
-12,285 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$72.45 - $94.81 $398,619 - $521,644
5,502 Added 81.11%
12,285 $1.15 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $540,265 - $720,490
6,783 New
6,783 $578,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Bank Of Nova Scotia Portfolio

Follow Bank Of Nova Scotia and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.